Tumor-Agnostic Therapies: Is This a Paradigm Shift in Cancer Care?
Tumor-agnostic therapies represent a radical shift in oncology. They abandon the traditional way of treating tumors based on cancer type and, instead, provide personalized options based on the genetic mutations. Today’s podcast is the 1st part of a 2-part series dedicated to agnostic treatments in cancer. Join us as Dr. Joshua Drago of Memorial Sloan Kettering Cancer Center shares his experience in the agnostic approach to cancer care. In this episode he discusses agnostic research and points out the advantages as well as the treatment limitations of agnostic therapeutics.
Resources on Agnostics:
The Evolving Landscape of Tissue-Agnostic Therapies in Precision Oncology
TAPUR (Targeted Agent & Profiling Study): The TAPUR Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of Food and Drug Administration (FDA)- approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Sarat Chandarlapaty Lab at Memorial Sloan Kettering Cancer Center
Meet the Guest of the Episode
Joshua Drago, MD, MS
Dr. Drago is a Medical Oncologist and Breast Cancer specialist at Memorial Sloan Kettering Cancer Center. Dr. Drago’s research efforts include clinical and translational projects across breast cancer subtypes, with a special focus on HER2-positive breast cancer and antibody-drug conjugates. He has been the recipient of the Brian Piccolo Endowed Cancer Research Fellowship Award, Coltman Scholars Award, METAVIVOR Early Career Investigator Award, ASCO/Conquer Cancer Foundation Young Investigator Award, and the K12 Paul Calabresi Career Development Award for Clinical Oncology. Dr. Drago received his medical degree from Harvard Medical School, completed residency training in Internal Medicine at Massachusetts General Hospital, and finished Fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center.
